Skip to main content

Table 4 Serum levels of sFas/sFasL and their correlations with clinicopathological features of patients with gastric adenocarcinoma

From: Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma

 

sFas (pg/ml)

sFasL (pg/ml)

 

N*

Mean ± SE.M†

P Value

N*

Mean ± SE.M†

P Value

Tumor invasion

      

   T1 & T2

5

228.66 ± 50.29

0.45

5

0.46 ± 0.44

0.93

   T3 & T4

36

227.73 ± 64.32

 

38

0.09 ± 0.03

 

Lymph node involvement

      

   N0

14

404.86 ± 150.62

0.044

14

0.24 ± 0.16

0.57

   N >0

28

273.00 ± 68.97

 

30

0.11 ± 0.03

 

Stage

      

   I & II

22

479.83 ± 151.47

0.2

23

0.22 ± 0.10

0.16

   III & IV

32

199.70 ± 28.16

 

34

0.09 ± 0.03

 

Grade

      

   Well Differentiated

11

392.19 ± 209.08

0.75

11

0.29 ± 0.20

0.92

   Moderatly Differentiated

15

307.88 ± 136.59

 

15

0.11 ± 0.05

 

   Poorly Differentiated

4

334.00 ± 232.12

 

5

0.11 ± 0.08

 

Tumor location

      

   Cardia

18

242.72 ± 62.78

0.53

18

0.03 ± 0.01

0.005

   Non-cardia

37

358.92 ± 99.61

 

40

0.21 ± 0.07

 
  1. * N: Number of samples
  2. † Mean ± SE.M: Mean Serum Range ± Standard Error of Mean
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us